dc.contributor.author | Alkan, Ali | |
dc.contributor.author | Oksuzoglu, Berna | |
dc.contributor.author | Ozdemir, Nuriye | |
dc.contributor.author | Sendur, M. A. Nahit | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | KILIÇKAP, SAADETTİN | |
dc.contributor.author | Utkan, Gungor | |
dc.contributor.author | AKBULUT, HAKAN | |
dc.contributor.author | ÇELİK, İSMAİL | |
dc.contributor.author | Abali, Huseyin | |
dc.contributor.author | ÜRÜN, YÜKSEL | |
dc.contributor.author | Yasar, H. Arzu | |
dc.contributor.author | Turna, Hande | |
dc.contributor.author | Esin, Ece | |
dc.contributor.author | Sedef, A. Murat | |
dc.date.accessioned | 2021-03-06T10:05:22Z | |
dc.date.available | 2021-03-06T10:05:22Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Yasar H. A. , Turna H., Esin E., Sedef A. M. , Alkan A., Oksuzoglu B., Ozdemir N., Sendur M. A. N. , Sezer A., KILIÇKAP S., et al., "Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study", JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.26, ss.267-272, 2020 | |
dc.identifier.issn | 1078-1552 | |
dc.identifier.other | av_e8b0e8a8-c0e5-4729-b5d3-d1b641ff6e43 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/152915 | |
dc.identifier.uri | https://doi.org/10.1177/1078155219840796 | |
dc.description.abstract | Objective | |
dc.language.iso | eng | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Eczacılık | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.title | Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF ONCOLOGY PHARMACY PRACTICE | |
dc.contributor.department | Ankara Üniversitesi , , | |
dc.identifier.volume | 26 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 267 | |
dc.identifier.endpage | 272 | |
dc.contributor.firstauthorID | 2278948 | |